Elder Pharma Posts Higher Net Revenue of Rs. 302.

71 Cr for Q4 Ended March 2010-1

1 - Up By 60%
* PAT grows by 11% in FY2011
* Shelcal K and Shelcal HD gaining traction
* Completes NCD program of Rs. 118.80 Cr and Rs. 73.00 Cr in two separate Tranch
es
* Launches I-Vit Plus; Launches Somazina Plus
Mumbai, India, May 11, 2011 -- Elder Pharmaceuticals Ltd (NSE- ELDERPHARM) ( htt
p://www.elderindia.com ) an integrated pharmaceuticals company headquartered in
Mumbai has posted robust results for the fourth quarter ended March 2011 (Q4 FY2
011). As per the consolidated unaudited provisional results taken on record on M
ay 10th, 2011, the income from operations has gone up to Rs 3,027.14 Crore for Q
4-FY2011 as compared to Rs. 1,896.94 Crore during the corresponding quarter in t
he previous year. The consolidated operating profit (PBIDT) too has gone up to R
s. 523.52 Crore for Q4 FY2011 reflecting a growth of 40% over the previous corre
sponding quarter's figure of Rs. 374.86 Crore. The consolidated Net Profit for Q
4 FY2011 stood at Rs. 172.76 Crore. The consolidated EPS on a non - annualized b
asis stood at Rs. 8.41 for Q4 FY2011 and at Rs. 30.03 for FY2011.
For the twelve months ended March 2011, the unaudited consolidated sales turnove
r is Rs. 9,592.03 Cr (previous 12 months- Rs. 7,208.98 Cr - audited) up by 33% a
nd the unaudited Net Profit is Rs. 616.76 Cr (previous 12 months - Rs 553.92 Cr
- audited) up by 11%.
During the quarter under review, the Company completed its NCD raising program t
o augment medium to long term resources including regular capital expenditure. F
irst tranche of Rs. 118.80 Crore and Second Tranche of Rs. 73.00 Crore were comp
leted on 23rd Dec'2010 and 31st March 2011 respectively.
The Company launched I-Vit Plus and Somazina Plus during the quarter under revie
w.
* I-Vit Plus is a blend of micro-nutrients helpful in providing adequate mineral
/vitamin and essential nutrient supplementation for correcting suboptimal vitami
n/mineral intake.
* Somazina Plus is a unique combination of Citicholine with Piracetam that impro
ves brain function and stimulates the central nervous system thus offering neuro
protection and enhancing cognition.
Elder Pharmaceuticals ( http://www.elderindia.com ) has presence in niche therap
eutic segments like Women's healthcare, Wound care, Nutraceuticals /vitamin Supp
lements, Cardiology, Diabetes, Dermatology, Antibiotics and neurology. It is the
market leader in calcium supplements (Shelcal), wound healing and injectable B1
2 vitamin. The company has a judicious mix of drug formulations, and active phar
ma ingredients (APIs). It has 6 manufacturing plants in India located in Maharas
htra, Uttarakhand & Himachal Pradesh. The company has a state-of-the-art Researc
h & Development Centre at Navi Mumbai which is recognized by the Department of S
cientific & Industrial Research, Ministry of Science & Technology. ( http://www.
elderindia.com ).
Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com